In last trading session, the stock price of Propanc Health Group Corp (OTCMKTS:PPCH) gained over 14% to close the day at $0.0360. The gains came at a share volume of 22.67 million compared to average share volume of 14.34 million.
Propanc Health reported the completion of its new website, incorporating vital new features that intends to improve the experience of the investors as well as the broader public. It comes at a time when the market participants are keen to know about the company’s unique technology, its existing operations and its outlook for the future and how it impacts the field of cancer.
Investor Relations web part of the new website showcases immediate release of the company’s PR as they are issued, and the automated release of SEC filings, financial statements, XBRL data and Insider Section 16 filings. Stock information data are updated on demand with twenty minute delay. The website also boasts an IR calendar that features upcoming media coverage and events, and an up-to-date FAQs section.
James Nathanielsz, the CEO of Propanc, expressed that they are pleased to report the new corporate website, after several months spent in planning and development. Propanc is now progressing towards an exciting phase, as they transition PRP into patient studies, and intends for an up-listing on a reputed national exchange platform. At this moment, the management felt it was a vital time to update on the depth of its scientific knowledge by highlighting on key points which the investors and broader public can understand.
Propanc hired Equisolve to design, advance and offer ongoing management for this new online platform. Equisolve is a main firm offering advanced communications solutions for public firms by integrating the firm’s IR website and corporate website on a single platform. The company intends to fast track the innovation of proenzyme based oncology products into clinical studies for pancreatic and ovarian cancers.